Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | MMP1 | P03956 | 1/20 | 0.30 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | MMP3 | P08254 | 1/20 | 0.30 |
| ▸ | MMP9 | P14780 | 1/20 | 0.30 |
| ▸ | MMP13 | P45452 | 1/20 | 0.30 |
| ▸ | KLK7 | P49862 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21295799 | 1.00 | TP53 (0.48) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL27912680 | 0.98 | TP53 (0.46) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL18651139 | 0.97 | TP53 (0.50) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL21768461 | 0.97 | TP53 (0.50) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL8557040 | 0.97 | TP53 (0.50) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL23673200 | 0.97 | TP53 (0.50) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL44463 | 0.97 | TP53 (0.50) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL29743149 | 0.97 | TP53 (0.50) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL12046593 | 0.97 | TP53 (0.50) | TP53CYP1A2GAACYP2C9PKM | |
| SCHEMBL29743150 | 0.97 | TP53 (0.50) | TP53CYP1A2GAACYP2C9PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105399622-B | A kind of method of use heavy constituent production of lactic acid potassium lactate | 武汉三江航天固德生物科技有限公司 | 2017-09-19 | — | — | CN | claimed |
| EP-2410031-B1 | BASE MATERIAL FOR SPRAYING COMPRISING LOW-MOLECULAR GELLING AGENT | NISSAN CHEMICAL CORP (JP) | 2019-04-24 | — | — | EP | disclosed |
| CN-105399622-B | A kind of method of use heavy constituent production of lactic acid potassium lactate | 武汉三江航天固德生物科技有限公司 | 2017-09-19 | — | — | CN | disclosed |
| CN-105399622-B | A kind of method of use heavy constituent production of lactic acid potassium lactate | 武汉三江航天固德生物科技有限公司 | 2017-09-19 | — | — | CN | disclosed |
| CN-105399622-B | A kind of method of use heavy constituent production of lactic acid potassium lactate | 武汉三江航天固德生物科技有限公司 | 2017-09-19 | — | — | CN | disclosed |
| US-9333158-B2 | Spray base material including low-molecular gelator | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2016-05-10 | — | — | US | disclosed |
| CN-102105553-B | Novel lipid dipeptides and gels | NISSAN CHEMICAL IND LTD | 2013-11-13 | — | — | CN | disclosed |
| US-20120035108-A1 | SPRAY BASE MATERIAL INCLUDING LOW-MOLECULAR GELATOR | KYUSHU UNIVERSITY (JP) | 2012-02-09 | — | — | US | disclosed |
| EP-2410031-A1 | BASE MATERIAL FOR SPRAYING COMPRISING LOW-MOLECULAR GELLING AGENT | Nissan Chemical Industries, Ltd. (JP) | 2012-01-25 | — | — | EP | disclosed |
| CN-102105553-A | Novel lipid dipeptides and gels | NISSAN CHEMICAL IND LTD | 2011-06-22 | — | — | CN | disclosed |
| CN-1052655-C | Human relaxin formulation | GENENTECH INC (US) | 2000-05-24 | — | — | CN | disclosed |
| US-5831130-A | Condensed phase preparation of 2,3-pentanedione | BOARD OF TRUSTEES OPERATING MICHIGAN STATE UNIVERSITY (US) | 1998-11-03 | — | — | US | disclosed |
| WO-1998047846-A1 | CONDENSED PHASE PREPARATION OF 2,3-PENTANEDIONE | MICHIGAN STATE UNIVERSITY (US) | 1998-10-29 | — | — | WO | disclosed |
| CN-1035619-A | HUMAN RELAXIN FORMULATION | GENENTECH INC (US) | 1989-09-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035108-A1 | SPRAY BASE MATERIAL INCLUDING LOW-MOLECULAR GELATOR | CUTA, DSG1, STMN1 | TP53 587/4885CYP1A2 3336/4885GAA 2501/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.